Augustine Asset Management Inc. Has $5.46 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Augustine Asset Management Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,733 shares of the biopharmaceutical company's stock after selling 3,113 shares during the quarter. Gilead Sciences makes up 1.6% of Augustine Asset Management Inc.'s holdings, making the stock its 13th biggest position. Augustine Asset Management Inc.'s holdings in Gilead Sciences were worth $5,461,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter valued at $35,000. Investment Research & Advisory Group Inc. lifted its holdings in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. Finally, Synergy Investment Management LLC acquired a new stake in Gilead Sciences during the 4th quarter valued at $40,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Up 2.8%

Shares of NASDAQ GILD opened at $110.67 on Friday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96. The stock has a market capitalization of $137.67 billion, a P/E ratio of 23.30, a PEG ratio of 0.72 and a beta of 0.29. The stock's fifty day moving average is $106.39 and its 200 day moving average is $103.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the business earned ($1.32) earnings per share. Gilead Sciences's revenue was down .3% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Bank of America lifted their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the transaction, the chief financial officer now owns 165,110 shares in the company, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,500 shares of company stock worth $5,236,245 over the last 90 days. Insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.